Holen Sie sich die Stockscreener-App
12.67
1.25%
-0.16
Schlusskurs vom Vortag:
$12.83
Offen:
$12.72
24-Stunden-Volumen:
810.89K
Relative Volume:
0.46
Marktkapitalisierung:
$1.44B
Einnahmen:
$655.35M
Nettoeinkommen (Verlust:
$-136.23M
KGV:
-10.37
EPS:
-1.2223
Netto-Cashflow:
$-75.68M
1W Leistung:
+18.19%
1M Leistung:
+7.28%
6M Leistung:
-12.50%
1J Leistung:
-18.68%
1-Tages-Spanne:
$12.50
$13.07
1-Wochen-Bereich:
$10.85
$13.17
52-Wochen-Spanne:
$9.82
$20.06
Novocure Ltd Stock (NVCR) Company Profile
Firmenname
Novocure Ltd
Sektor
Branche
Telefon
44 (0)15 3475 6700
Adresse
NO. 4 THE FORUM, ST. HELIER
Compare NVCR vs ABT, SYK, MDT, BSX, EW
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NVCR
Novocure Ltd
|
12.67 | 1.46B | 655.35M | -136.23M | -75.68M | -1.2223 |
ABT
Abbott Laboratories
|
96.00 | 168.22B | 45.13B | 6.28B | 7.40B | 3.5895 |
SYK
Stryker Corp
|
338.34 | 131.49B | 25.12B | 3.25B | 4.28B | 8.3984 |
MDT
Medtronic Plc
|
85.00 | 110.66B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
60.99 | 95.46B | 20.08B | 2.89B | 3.66B | 1.9391 |
EW
Edwards Lifesciences Corp
|
81.44 | 46.69B | 6.07B | 1.06B | 1.34B | 1.8063 |
Novocure Ltd Stock (NVCR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-25 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2025-07-08 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2024-12-02 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2024-10-16 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2023-11-20 | Fortgesetzt | JP Morgan | Neutral |
| 2023-08-28 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2023-08-08 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2023-08-04 | Eingeleitet | SVB Securities | Outperform |
| 2023-07-31 | Hochstufung | Evercore ISI | Underperform → In-line |
| 2023-06-07 | Hochstufung | Wedbush | Underperform → Neutral |
| 2023-05-16 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2023-03-17 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2023-01-06 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2023-01-05 | Bestätigt | H.C. Wainwright | Buy |
| 2022-11-29 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2022-10-24 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2022-07-05 | Herabstufung | Evercore ISI | In-line → Underperform |
| 2022-05-16 | Eingeleitet | H.C. Wainwright | Buy |
| 2022-02-08 | Eingeleitet | Loop Capital | Buy |
| 2022-02-02 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2022-01-20 | Hochstufung | Truist | Hold → Buy |
| 2022-01-03 | Hochstufung | Evercore ISI | Underperform → In-line |
| 2021-07-01 | Herabstufung | Mizuho | Buy → Neutral |
| 2021-04-14 | Herabstufung | Wedbush | Neutral → Underperform |
| 2021-01-25 | Bestätigt | Piper Sandler | Overweight |
| 2020-09-23 | Eingeleitet | Northland Capital | Outperform |
| 2020-09-18 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2020-09-17 | Herabstufung | Truist | Buy → Hold |
| 2020-06-01 | Fortgesetzt | Oppenheimer | Perform |
| 2020-05-01 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2020-04-09 | Herabstufung | Evercore ISI | In-line → Underperform |
| 2020-03-05 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2020-01-02 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2019-07-29 | Hochstufung | SunTrust | Hold → Buy |
| 2019-07-26 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2019-07-26 | Herabstufung | Wedbush | Outperform → Neutral |
| 2019-03-20 | Eingeleitet | SunTrust | Hold |
| 2018-11-02 | Herabstufung | Wells Fargo | Outperform → Market Perform |
| 2018-07-16 | Eingeleitet | Evercore ISI | Outperform |
| 2018-04-18 | Bestätigt | Mizuho | Buy |
| 2018-02-23 | Bestätigt | Mizuho | Buy |
| 2017-05-24 | Hochstufung | Wells Fargo | Market Perform → Outperform |
| 2016-07-29 | Bestätigt | Wedbush | Outperform |
| 2016-01-19 | Eingeleitet | Barclays | Underweight |
| 2015-12-02 | Eingeleitet | Deutsche Bank | Hold |
Alle ansehen
Novocure Ltd Aktie (NVCR) Neueste Nachrichten
Total debt per share of NovoCure Ltd. – SWB:038 - TradingView
NovoCure Ltd stock (JE00B6T5S470): Is tumor treating fields therapy strong enough to unlock new upsi - AD HOC NEWS
[DEF 14A] NovoCure Ltd Definitive Proxy Statement - Stock Titan
NovoCure Ltd stock (JE00B6T5S470): Does tumor treating fields therapy hold the key to oncology break - AD HOC NEWS
NovoCure Ltd (NVCR) Stock Up 3.8% and Still Undervalued -- GF Sc - GuruFocus
NVCR Reiterated by Wedbush -- Price Target Maintained at $18.00 - GuruFocus
Tangible book value per share of NovoCure Ltd. – GETTEX:038 - TradingView — Track All Markets
NovoCure's (NVCR) Neutral Rating Reaffirmed at Wedbush - MarketBeat
Is NovoCure’s (NVCR) Leadership Consolidation Clarifying Its Innovation Strategy Or Complicating Governance Signals? - Sahm
NovoCure Ltd (NVCR) Stock Up 5.4% and Still Undervalued -- GF Sc - GuruFocus
NVCR SEC FilingsNovocure 10-K, 10-Q, 8-K Forms - Stock Titan
Assessing NovoCure (NVCR) Valuation After Prolonged Share Price Weakness And Undervalued Narrative - simplywall.st
NovoCure Unifies Clinical And Innovation Roles As Market Discounts Persist - Sahm
NovoCure Ltd (NVCR) Stock Down 3.8% -- Now Undervalued? GF Score: 66/100 - GuruFocus
NovoCure Limited Increases Compensation for Dr. Uri Weinberg Upon Appointment as Chief Medical Officer - Minichart
Novocure increases executive compensation as Uri Weinberg takes on dual roles By Investing.com - Investing.com South Africa
Novocure increases executive compensation as Uri Weinberg takes on dual roles - Investing.com
NovoCure appoints Uri Weinberg as Chief Medical Officer alongside Chief Innovation Officer - TradingView
NovoCure (NASDAQ: NVCR) boosts pay as Uri Weinberg assumes CMO duties - Stock Titan
NovoCure (BSP:N2VC34) Net Investment Income - GuruFocus
NovoCure (BSP:N2VC34) Other Assets for Insurance Companies - GuruFocus
NovoCure (BSP:N2VC34) Dividend Yield % : 0.00% (As of Apr. 09, 2026) - GuruFocus
NovoCure (BSP:N2VC34) Other Net Income (Loss) : R$0 Mil (TTM As of Dec. 2025) - GuruFocus
NovoCure (BSP:N2VC34) 6-1 Month Momentum % : N/A% (As of Apr. 09, 2026) - GuruFocus
NovoCure (BSP:N2VC34) Cash Flow from Discontinued Operations : R$0 Mil (TTM As of Dec. 2025) - GuruFocus
NovoCure (BSP:N2VC34) PEG Ratio : N/A (As of Apr. 09, 2026) - GuruFocus
NovoCure (BSP:N2VC34) Gross-Profit-to-Asset % : 49.36% (As of Dec. 2025) - GuruFocus
NovoCure (BSP:N2VC34) Shiller PE Ratio : (As of Apr. 09, 2026) - GuruFocus
NovoCure (BSP:N2VC34) Purchase Of Investment : R$-4,539 Mil (TTM As of Dec. 2025) - GuruFocus
NovoCure (BSP:N2VC34) Operating Income : R$-851 Mil (TTM As of Dec. 2025) - GuruFocus
NovoCure (BSP:N2VC34) Minority Interest : R$0.00 Mil (As of Dec. 2025) - GuruFocus
NovoCure (BSP:N2VC34) 3-1 Month Momentum % : N/A% (As of Apr. 09, 2026) - GuruFocus
NovoCure (BSP:N2VC34) Investments And Advances : R$0 Mil (As of Dec. 2025) - GuruFocus
NovoCure (BSP:N2VC34) Non Operating Income : R$0 Mil (TTM As of Dec. 2025) - GuruFocus
NovoCure (BSP:N2VC34) 1-Year Sharpe Ratio : N/A (As of Apr. 09, 2026) - GuruFocus
NovoCure (BSP:N2VC34) Retained Earnings : R$-7,040 Mil (As of Dec. 2025) - GuruFocus
NovoCure (BSP:N2VC34) Interest and Commission Paid - GuruFocus
NovoCure (BSP:N2VC34) Inventories, Other : R$-0 Mil (As of Dec. 2025) - GuruFocus
NovoCure (BSP:N2VC34) Forward Dividend Yield % : 0.00% (As of Apr. 09, 2026) - GuruFocus
NovoCure (BSP:N2VC34) Graham Number : R$N/A (As of Dec. 2025) - GuruFocus
NovoCure (BSP:N2VC34) PE Ratio (TTM) : At Loss (As of Apr. 09, 2026) - GuruFocus
NovoCure (BSP:N2VC34) Cyclically Adjusted PS Ratio : (As of Apr. 09, 2026) - GuruFocus
NovoCure (BSP:N2VC34) Other Long-Term Liabilities : R$0 Mil (As of Dec. 2025) - GuruFocus
NovoCure (BSP:N2VC34) Other Current Assets : R$106 Mil (As of Dec. 2025) - GuruFocus
NovoCure (BSP:N2VC34) Gross Property, Plant and Equipment : R$1,180 Mil (As of Dec. 2025) - GuruFocus
NovoCure (BSP:N2VC34) Total Operating Expense : R$3,550 Mil (TTM As of Dec. 2025) - GuruFocus
NovoCure (BSP:N2VC34) Purchase Of Business : R$0 Mil (TTM As of Dec. 2025) - GuruFocus
NovoCure (BSP:N2VC34) Sale Of Business : R$0 Mil (TTM As of Dec. 2025) - GuruFocus
NovoCure (BSP:N2VC34) Dividend Payout Ratio : 0.00 (As of Dec. 2025) - GuruFocus
NovoCure (BSP:N2VC34) Cyclically Adjusted Price-to-FCF : (As of Apr. 09, 2026) - GuruFocus
NovoCure (BSP:N2VC34) Net Policyholder Benefits/Claims - GuruFocus
Finanzdaten der Novocure Ltd-Aktie (NVCR)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.74%
1.72%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):